Status:
COMPLETED
Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Genetic Underpinning of Substance Abuse
Polymorphism-genetic
Eligibility:
All Genders
18+ years
Brief Summary
Background: \- Differences in peoples genes can make them respond to drugs in different ways. Methadone and buprenorphine are two drugs used to treat drug addiction. A study showed that African Ameri...
Detailed Description
The NIDA Clinical Trials Network s (CTN) START Study was designed to look at the pharmacogenetics of treatment response. The CTN investigators found that an intronic SNP (rs678849) in the gene for the...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Current or former participation in an Archway methadone or buprenorphine treatment study;
- Age 18 or older;
- Meet DSM-IV criteria for opioid dependence;
- Self-identified as African American, with at least 3 African American grandparents by self-report;
- At least 12 weeks of continuous treatment with a stable dose (no taper \>7 days in length) of either buprenorphine or methadone, in a treatment regimen in which the physician considers dose increases in response to withdrawal symptoms, craving, or evidence of illicit opioid use by urine screens;
- At least 10 weeks of urine results available for analysis in that 12-week period, with no more than 6 consecutive urine data points missing, a requirement that should limit non-compliance as a factor;
- Able to speak and read English sufficiently to provide informed consent;
- Former participants only: have consented to future contact .
- EXCLUSION CRITERIA:
- (1) Inability to give informed consent.
Exclusion
Key Trial Info
Start Date :
August 23 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT02225184
Start Date
August 23 2014
End Date
December 31 2018
Last Update
January 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute on Drug Abuse
Baltimore, Maryland, United States, 21224